Qube Research & Technologies LTD Allovir, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Allovir, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 14,539 shares of ALVR stock, worth $140,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,539
Previous 34,341
57.66%
Holding current value
$140,010
Previous $27,000
77.78%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ALVR
# of Institutions
49Shares Held
21.1MCall Options Held
41KPut Options Held
100-
Siren, L.L.C. New York, NY6.6MShares$63.5 Million0.12% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$29.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$25.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.4 Million0.06% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ664KShares$6.4 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $896M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...